Generics 11

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Tirofiban manufacturers

11 products found

Filters

11 products found

tirofiban

Bags for injection/infusion 50 mcg/ml - 250 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
France , Vietnam
Registered in
France
Available for
Distribution only
Manufacturer #15084
This European pharmaceutical company specializes in the Central Nervous System (CNS) and Hospital Injectables. They operate in a niche market focusing on treatments for debilitating conditions like chronic pain and addiction. With a strong commitment to patient care, they are actively seeking new opportunities to expand their product portfolio and geographical reach, particularly within the EU market. Their core therapy areas include CNS disorders, pain management, and addiction treatment. The company has a robust research and development (R&D) program and actively seeks strategic partnerships to further its growth. This company develops and produces both prescription and over-the-counter (OTC) medications in various dosage forms, including injectables, solids, and liquids, which are manufactured under EU and other GMP standards. They hold numerous patents for their innovative drug formulations and have a track record of successful acquisitions, demonstrating their commitment to expanding their presence in the pharmaceutical industry. This company has a solid presence in the European market with an expansion into the Asia region, and is actively pursuing opportunities to expand its global footprint.

Manufacturer usually replies in 18 days

tirofiban

Solution for infusion 50 mcg/ml - 250 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Iran , Vietnam
Available for
Licensing with supply
Comments
Indication: Thrombotic Events; Status: MA granted
Manufacturer #385

A pharmaceutical manufacturer based in the EU that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, Africa, and Asia for 60+ years. Key production lines are Rx and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 10 days

tirofiban

Vials, injection 250 mcg/ml - 50 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Iran , Vietnam
Available for
Licensing with supply
Comments
Indication: Thrombotic Events; Status: MA granted
Manufacturer #385

A pharmaceutical manufacturer based in the EU that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, Africa, and Asia for 60+ years. Key production lines are Rx and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 10 days

Want to see all 11 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Tirofiban

Tirofiban is an antiplatelet drug. Tirofiban reduces the frequency of thrombotic cardiovascular events. These events combine endpoint of death, myocardial infarction, or refractory ischemia/repeat the cardiac procedure in patients with non-ST elevation acute coronary syndrome. Its actions prevent blood from clotting during episodes of chest pain or a heart attack, or during procedures related to the blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein receptor. It works by inhibiting platelet aggregation. Tirofiban is marketed under the brand name Aggrastat amongst others.  Baxter Healthcare Corporation first filed for a patent of Tirofiban. It was first approved in the US in 2000. Medicare Pharma in the USA markets it.

Forms and Dose:

Tirofiban is available for premixed IV infusion solution in 5mg/100mL and 12.5mg/250mL, and for IV solution vials in 5mg/100mL vialand 3.75mg/15mL bolus vials. In the treatment of Non-ST Elevation Acute Coronary Syndrome, the recommended loading dose is 25 mcg per kilo IV infused within 5 minutes, to reduce the rate of thrombotic cardiovascular events. The post-loading dose is limited to 0.15 mcg per kilo per minute of IV for up to 18 hr. 

The price of Tirofiban:

In the USA, the average price consumers pay for the intravenous solution of 250 mcg/mL is around $68 for a supply of 15 millilitres. However, the price in India for a generic version of this medicine is lower at USD200 for a supply of 50ml. 

How does Tirofiban work?

Tirofiban’s action provide relief by preventing the formation of blood clots during chest pain or heart attack episodes, or while undergoing a procedure related to the blocked coronary artery. Its primary action inhibits platelet aggregation. When administered intravenously, as per the recommended regimen, more than 90% inhibition is attained within 30-minutes of the infusion. 

Finding Tirofiban Manufacturers and Suppliers:

The best way to find and gain access to Tirofiban’s manufacturers and suppliers is to make through Pipelinepharma's global B2B online marketplace for medicines and other pharmaceuticals. In the normal way, finding trusted manufacturers and supplies of specific drugs like Tirofiban can be a time-consuming challenge, but with Pipelinepharma's simple search engine and network of proven partners, the whole process becomes a lot easier. The patient needs to do to get started is to make use of our integrated search engine and start looking for suppliers or manufacturers of this drug to work with and fine-tune his search results using various filters too, letting him search for it from specific countries.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation